Sandbagging an Alzheimer’s Treatment – WSJ

The Food and Drug Administration evaluates drugs for safety and effectiveness, but now the Centers for Medicare and Medicaid Services want to act as political scrutiny of FDA decisions. Last week, CMS refused to cover a novel Alzheimer’s treatment for millions of patients because it disagreed with FDA approval.

Biogen’s Aduhelm is the first FDA-approved treatment shown to slow the progression of Alzheimer’s disease. But the drug is now embroiled in a political battle. The public health left thinks the FDA is approving too many new expensive drugs with little benefit and wants CMS to overrule the drug agency. Progressives are hailing CMS Aduhelm’s decision as a precedent for the agency to restrict access to new FDA-approved treatments. Aduhelm is the target today, but cancer and gene therapies could be next. Sandbagging an Alzheimer’s Treatment – WSJ

Ethan Gach is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button